Clinical Trial

Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

Study acronym: TROJAN-C
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2017-12-22; most recent amendment 2026-01-21.
Status change: Active, Not Recruiting → Recruiting 2026-01-21
Status change: Recruiting → Active, Not Recruiting 2023-01-25
Status change: Not Yet Recruiting → Recruiting 2018-03-22
Trial Details
NCT Number NCT03383419
Lead Sponsor Baylor Research Institute
Conditions Heart Failure
Enrollment 15 participants
Start Date 2018-03-20
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-22